CD4 and non-small cell lung carcinoma: Results of several clinical studies performed in China have demonstrated that improvements of percentages of total T lymphocytes, helper T lymphocytes, cytotoxic T lymphocytes, CD4+/ CD8+, and natural killer cells, which are indicators of cellular immune function, are observed in NSCLC patients[11, 15, 16, 20, 24, 28].